Review
Oncology
Yu-Ge Zhu, Bu-Fan Xiao, Jing-Tao Zhang, Xin-Run Cui, Zhe-Ming Lu, Nan Wu
Summary: Esophageal cancer is a highly aggressive and malignant cancer that can be treated with surgery, chemotherapy, radiotherapy, and immunotherapy. Immunotherapy, specifically using genetically-modified cells to target cancer cells, has shown promising results in clinical trials.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Florian Maerkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L. Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Mueller, Lina Majed, Matthias Seifert, Anna-Kristina Kluever, Theo Lorenzini, Ruth Gruenmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P. Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold
Summary: Melanoma is an immune sensitive disease, and immune check point blockade has shown activity. However, TIL therapy after ICB failure has shown promising efficacy, indicating the potential of cellular therapies. To overcome limitations of TIL treatment, a controlled adoptive cell therapy approach using synthetic agonistic receptors and bispecific antibodies targeting melanoma-associated antigens is proposed.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biotechnology & Applied Microbiology
Jingting Min, Chirong Long, Lu Zhang, Jiakang Duan, Honglian Fan, Fei Chu, Zhenghong Li
Summary: Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy, and CAR-T cell therapy targeting c-Met shows potential as a therapeutic strategy. In vitro and in vivo experiments demonstrated that c-Met CAR-T cells exhibit enhanced cytotoxicity against NSCLC cells.
Article
Oncology
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C. Williams
Summary: The use of universal CAR T cells shows promise in improving the efficacy of cancer treatment and has broad potential applications.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Michael Kilian, Theresa Bunse, Wolfgang Wick, Michael Platten, Lukas Bunse
Summary: Malignant glioma remains a devastating disease for which standard treatment is limited to resection and radiochemotherapy. Despite promising results in other tumor types, CAR T cell therapy for glioma has yet to show significant clinical efficacy. The emerging field of transgenic TCR therapy may offer a potent alternative for overcoming antigenic limitations in glioma cell therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Natalia Plewa, Lucia Poncette, Thomas Blankenstein
Summary: This study suggests that HLA-DR4-restricted TCRs specific for the TGF beta R2(-1) recurrent neoantigen could be valuable candidates for adoptive T cell therapy in cancer patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Christopher A. Pennell, Heather Campbell, Meghan D. Storlie, Sara Bolivar-Wagers, Mark J. Osborn, Yosef Refaeli, Michael Jensen, Sophie Viaud, Travis S. Young, Bruce R. Blazar
Summary: Current FDA-approved CAR-T cell therapies for B-cell malignancies are effective but can increase morbidity and mortality. This study compared the performances of regulatable and constitutively active CAR-T cells, and found that regulatable CAR-T cells have the potential for improved efficacy and reduced toxicity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Lauren C. Cutmore, John F. Marshall
Summary: CAR T cells are a type of immunotherapy that has revolutionised the treatment of haematological malignancies by genetically modifying a patient's own cells to target and kill cancer cells. However, obstacles such as the individual production of CAR T cells result in variability in the product, longer wait times for treatment, and higher costs. Novel approaches utilizing allogeneic cells, known as off the shelf CAR T cells, have emerged to overcome these challenges.
Review
Biochemistry & Molecular Biology
Rodrigo C. C. De Marco, Hector J. J. Monzo, Paivi M. Ojala
Summary: With the continuous advancements in immunotherapy and precision medicine, adoptive cell therapy (ACT) has emerged as a new treatment approach in oncology. Chimeric antigen receptor (CAR) T cells, genetically modified lymphocytes, have shown promising results in targeting and killing cancer cells. Commercialization of CAR T cell therapy has paved the way for future bright developments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Celia Martin-Otal, Aritz Lasarte-Cia, Diego Serrano, Noelia Casares, Enrique Conde, Flor Navarro, Ines Sanchez-Moreno, Marta Gorraiz, Patricia Sarrion, Alfonso Calvo, Carlos E. De Andrea, Jose Echeveste, Amaia Vilas, Juan Roberto Rodriguez-Madoz, Jesus San Miguel, Felipe Prosper, Sandra Hervas-Stubbs, Juan Jose Lasarte, Teresa Lozano
Summary: This study demonstrates the feasibility and efficacy of targeting the tumor-specific fibronectin splice variant EDA with CAR-T cells, providing a potential therapeutic option for different types of cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Laetitia Pinte, Amy Cunningham, Helene Trebeden-Negre, Sarah Nikiforow, Jerome Ritz
Summary: CAR and TCR therapies have shown unprecedented growth since the first genetically-engineered clinical trial in 2003, with the USA, China, and Europe emerging as major research sites. Novel targets, genetic constructs, and manufacturing strategies are being developed to optimize efficacy and safety in treating various types of cancer.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Renee Poels, Esther Drent, Roeland Lameris, Afroditi Katsarou, Maria Themeli, Hans J. van der Vliet, Tanja D. de Gruijl, Niels W. C. J. van de Donk, Tuna Mutis
Summary: iNKT cells armed with CD38 and BCMA-CARs effectively eliminate MM cells without compromising their TCR-mediated cytotoxicity. These CAR iNKT cells show promising therapeutic potential with minimal impact on normal hematopoietic cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Huanpeng Chen, Yuying Yang, Yuqing Deng, Fengjiao Wei, Qingyu Zhao, Yongqi Liu, Zhonghua Liu, Bolan Yu, Zhaofeng Huang
Summary: This study developed CAR-T cells that can secrete a CD47 blocker, enhancing the therapeutic efficacy of CAR-T cells in solid tumor therapy. The results showed that these CAR-T cells significantly reduced tumor burden, prolonged survival, and modulated the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Audrey Page, Julie Hubert, Floriane Fusil, Francois-Loic Cosset
Summary: Immunotherapy strategies utilizing B cells have shown promising results in reducing tumor growth and enhancing antitumoral immune responses. By modifying B cells through various methods such as increasing antigen presentation or antibody secretion, their therapeutic role can be enhanced for potential cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Catherine M. Ade, Matthew J. Sporn, Sudipto Das, Zhiya Yu, Ken-ichi Hanada, Yue A. Qi, Tapan Maity, Xu Zhang, Udayan Guha, Thorkell Andresson, James C. Yang
Summary: This article introduces a method of using mass spectrometry to identify common tumor-specific neoepitopes derived from mutated oncogenes, and develop TCRs based on these data. The results of the study show that this method successfully identified precise neoepitopes derived from KRAS, EGFR, BRAF, and PIK3CA presented by HLA-A*03:01 and/or HLA-A*11:01 across multiple biological replicates.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Multidisciplinary Sciences
Yukiko Kiniwa, Jiang Li, Mingjun Wang, Chuang Sun, Jeffrey E. Lee, Rong-Fu Wang, Helen Y. Wang
Article
Immunology
Xiao Yu, Baowei Cai, Mingjun Wang, Peng Tan, Xilai Ding, Jian Wu, Jian Li, Qingtian Li, Pinghua Liu, Changsheng Xing, Helen Y. Wang, Xin-zhuan Su, Rong-Fu Wang
Article
Oncology
Guru Sonpavde, Mingjun Wang, Leif E. Peterson, Helen Y. Wang, Teresa Joe, Martha P. Mims, Dov Kadmon, Michael M. Ittmann, Thomas M. Wheeler, Adrian P. Gee, Rong-Fu Wang, Teresa G. Hayes
INVESTIGATIONAL NEW DRUGS
(2014)
Article
Oncology
Yan Xia, Xiaopeng Tian, Juntao Wang, Dongjuan Qiao, Xianhao Liu, Liang Xiao, Wenli Liang, Dongcheng Ban, Junjun Chu, Jiaming Yu, Rongfu Wang, Geng Tian, Mingjun Wang
Article
Multidisciplinary Sciences
Xiao Yu, Yang Du, Chunmei Cai, Baowei Cai, Motao Zhu, Changsheng Xing, Peng Tan, Meng Lin, Jian Wu, Jian Li, Mingjun Wang, Helen Y. Wang, Xin-zhuan Su, Rong-Fu Wang
NATURE COMMUNICATIONS
(2018)
Article
Cell Biology
Huishan Wang, Yuan Xia, Jiaming Yu, Hong Guan, Zhengsheng Wu, Dongcheng Ban, Mingjun Wang
Review
Immunology
Lei Chen, Dongjuan Qiao, Juntao Wang, Geng Tian, Mingjun Wang
IMMUNOLOGY LETTERS
(2019)
Article
Immunology
Yipeng Ma, Jiayu Ou, Tong Lin, Lei Chen, Juntao Wang, Dongjuan Qiao, Shuoyan Lai, Chaojun Duan, Yuanda Cheng, Ruimin Chang, Chunfang Zhang, Mingjun Wang
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2020)
Article
Immunology
Yipeng Ma, Fenglan Liu, Tong Lin, Lei Chen, Aixin Jiang, Geng Tian, Morten Nielsen, Mingjun Wang
Summary: The study identified 7 epitopes derived from 4 SARS-CoV-2 proteins, with most peptides being HLA-II-restricted and inducing CD4 + T cell-dependent responses. These findings suggest the presence of pre-existing T cells targeting all SARS-CoV-2-encoded proteins in unexposed populations.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Immunology
Hao Ren, Kunkun Cao, Mingjun Wang
Summary: T-cell therapy with ex-vivo expansion shows promise in cancer treatment, with differentiation status of infused T cells playing a crucial role in their persistence and antitumor immunity. Strategies to produce less differentiated T cells have been developed, and infusion of T cells with less differentiated phenotypes has shown better clinical outcomes. Key phenotypic molecules such as CD27+, CCR7+, and CD62L+ are recommended for evaluating strategies to enhance stemness in differentiation phenotypes of T cells. Future studies may reveal highly clinically relevant differentiation phenotypes for specific T-cell production methods or cancer patient subtypes, offering the advantages of precision medicine.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Lei Chen, Lianhua Dong, Yipeng Ma, Juntao Wang, Dongjuan Qiao, Geng Tian, Mingjun Wang
Summary: The study introduces a novel T cell receptor (TCR) cloning method that can efficiently identify high-quality TCRs with simplified procedures and low cost.
Article
Genetics & Heredity
Wenyujing Zhou, Weihong Chen, Xiaochun Wan, Changru Luo, Xin Du, Xiaoqing Li, Qian Chen, Ruiwen Gao, Xiaohan Zhang, Mei Xie, Mingjun Wang
Summary: The study showed that anti-CD19 CAR T-cell therapy is effective in treating relapsed/refractory B-cell lymphomas, and the side effects of CAR T-cell therapy can be properly managed. CAR T-cell therapy has high efficacy and showed no side effects in the treatment of minimal residual disease (MRD) in B-cell lymphomas (NCT03685786, NCT02456350).
FRONTIERS IN GENETICS
(2022)
Article
Biochemical Research Methods
Yipeng Ma, Fenglan Liu, Bin Li, Hong Zhou, Dongjuan Qiao, Lijuan Deng, Hao Wu, Fuyuan Fang, Youyu Wang, Da Yao, Guilin Hu, Youhui Qian, Mingjun Wang
Summary: TCR-T cell therapy has shown promising efficacy in treating malignant cancers, but the range of reported TCRs is still limited. Tumor infiltrating lymphocytes (TILs) are natural sources of tumor-reactive T cells and TCRs. In this study, an RNA-based preamplification step was included in the single-cell TCR sequencing, providing a rapid and cost-effective approach for identifying tumor-reactive TCRs. This method has the potential to be valuable for the development of TCR-T therapies for solid cancers.
JOURNAL OF IMMUNOLOGICAL METHODS
(2022)
Article
Gastroenterology & Hepatology
Yipeng Ma, Jiayu Ou, Tong Lin, Lei Chen, Junhui Chen, Mingjun Wang
Summary: This study presents an HBV-specific TCR identification method that does not require the TCR singularization process, using ranking-based and alpha-beta chain mixture-based strategies. These strategies are effective for identifying HBV-specific TCRs and may be used for treating HBV-related HCC.
HEPATOLOGY COMMUNICATIONS
(2021)
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.